Each year, the Down syndrome community and our supporters – family, friends, businesses, organizations and…
Kate O’NeillMarch 21, 2023
Parent, advocate, and published author, Steve Friedman has used his family's recent experiences to help…
Kate O’NeillMarch 15, 2023
"Alzheimer's meds are here. But for the Down syndrome community, it's still the 1980s" by…
Kate O’NeillMarch 2, 2023
2/22/2023 (Burlington, MA) – Today the LuMind IDSC Foundation, a leading national Down syndrome research…
Kate O’NeillFebruary 23, 2023
On Friday, January 6, the U.S. Food & Drug Administration (FDA) granted accelerated approval for…
Kate O’NeillJanuary 10, 2023
At an Alzheimer’s disease research conference last week, new clinical trial data was presented for…
Kate O’NeillDecember 5, 2022
LuMind IDSC and the Down Syndrome Clinical Trials Network are pleased to announce the launch…
Kate O’NeillNovember 16, 2022
Eisai, a Japanese pharmaceutical company, and its partner Biogen, a Massachusetts-based biotechnology company, recently announced…
Kate O’NeillNovember 1, 2022
In a recent report, the National Task Group on Intellectual Disabilities and Dementia Practices (NTG)…
Kate O’NeillOctober 17, 2022